Figure 2: Inhibition of TGFβRII signaling reduces primary tumor size and metastasis of CMT-luc cells.

(A) Western blot for TGFβRII in untransduced parental CMT-luc cells or CMT-luc cells transduced with control or TGFβRII targeting shRNA. (B) qRT-PCR of TGFβRII expression in parental CMT-luc and CMT-luc cells transduced with control shRNA or TGFβRII targeting shRNA (602 or 531). (C,D) WT mice were orthotopically injected with CMT-luc cells expressing control shRNA or the TGFβRII targeting shRNA 602. Mice were harvested to measure metastasis 5 weeks post injection. There were 16 mice injected with the control shRNA CMT-luc cells and 19 mice injected with the TGFβRII targeting shRNA CMT-luc cells. The data for all mice injected is reported. (E,F) WT mice were orthotopically injected with CMT-luc cells and treated with the TGFβRI inhibitor SB431542 (10 mg/kg) or vehicle control (1:1 DMSO:PBS) starting at the time of injection and continuing 5 days a week for 5 weeks. (D,F) Primary tumor size was measured by caliper and reported as the tumor volume in mm³. (E,F) Incidence of metastasis reported as the percent of mice with metastasis to the other lobes of the lung (secondary lung) or liver, as measured by bioluminescence (*p<0.05).